Literature DB >> 4550059

Proceedings: Clinical trial of autogenous tumor vaccine for treatment of osteogenic sarcoma.

C M Southam, R C Marcove, A G Levin, H J Buchsbaum, V Miké.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 4550059

Source DB:  PubMed          Journal:  Proc Natl Cancer Conf        ISSN： 0077-3670


× No keyword cloud information.
  3 in total

1.  Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody.

Authors:  Tomohide Tsukahara; Makoto Emori; Kenji Murata; Takahisa Hirano; Norihiro Muroi; Masanori Kyono; Shingo Toji; Kazue Watanabe; Toshihiko Torigoe; Vitaly Kochin; Hiroko Asanuma; Hiroshi Matsumiya; Keiji Yamashita; Tetsuo Himi; Shingo Ichimiya; Takuro Wada; Toshihiko Yamashita; Tadashi Hasegawa; Noriyuki Sato
Journal:  J Biol Chem       Date:  2014-06-24       Impact factor: 5.157

2.  Anti-TGF-β antibody combined with dendritic cells produce antitumor effects in osteosarcoma.

Authors:  Masanori Kawano; Ichiro Itonaga; Tatsuya Iwasaki; Hiroyuki Tsuchiya; Hiroshi Tsumura
Journal:  Clin Orthop Relat Res       Date:  2012-03-14       Impact factor: 4.176

3.  HLA-A*0201-restricted CTL epitope of a novel osteosarcoma antigen, papillomavirus binding factor.

Authors:  Tomohide Tsukahara; Satoshi Kawaguchi; Toshihiko Torigoe; Akari Takahashi; Masaki Murase; Masanobu Kano; Takuro Wada; Mitsunori Kaya; Satoshi Nagoya; Toshihiko Yamashita; Noriyuki Sato
Journal:  J Transl Med       Date:  2009-06-12       Impact factor: 5.531
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.